The HOPE4MCI Alzheimer’s Trial is a global Phase 3 clinical research study that will assess the effectiveness and safety of an investigational medication to determine if it can slow the progression of symptoms associated with aMCI and prevent or delay the onset of Alzheimer’s dementia.

Who can participate?

  • People whose symptoms are consistent with a diagnosis of aMCI
  • People who have a positive PET scan with florbetapir F18 injection (Amyvid™ beta-amyloid scan)

A PET scan, or positron emission tomography, is a test that uses a special type of camera and a tracer (a unique chemical) to look at organs in the body.

What happens during the study?

  • Study volunteers will be assessed for entry into the clinical research study. You will be asked to sign a consent form and give your medical health history and current medicines you may be taking. Additionally, some initial medical and cognitive testing will be preformed to find out if you can be in the study.
  • Study volunteers will receive the investigational medication, a once-a-day oral tablet, or a placebo once-a-day oral tablet over a period of 18 months. The investigational medication is an FDA-approved and commonly prescribed medication for epilepsy, but during this research trial, the dose will be considerably lower.

Study volunteers will be assessed medically and by clinical/cognitive rating scales and receive a magnetic resonance imaging (MRI) scan that measures brain structure approximately every six months.

We expect the HOPE4MCI study to begin in 2018. As we get closer to the study initiation, a full list of eligibility criteria will be available at www.clinicaltrials.gov.

Learn more about clinical trials.

Keep Me Posted

As we get closer to the trial, we will provide more details so you can better understand the eligibility requirements of the study. If you would like updates when new information is available on HOPE4MCI.org, sign up for our email alerts.